PMID- 26885106
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20160217
LR  - 20200930
IS  - 1940-5901 (Print)
IS  - 1940-5901 (Electronic)
IS  - 1940-5901 (Linking)
VI  - 8
IP  - 11
DP  - 2015
TI  - Effect of rosuvastatin dose-loading on serum sLox-1, hs-CRP, and postoperative 
      prognosis in diabetic patients with acute coronary syndromes undergoing selected 
      percutaneous coronary intervention (PCI).
PG  - 21565-71
AB  - OBJECTIVE: To investigate the effect of rosuvastatin dose-loading on serum levels 
      of lectin-like oxidized low-density lipoprotein receptor-1 (Lox-1) and 
      high-sensitivity c-reactive protein (hs-CRP) and postoperative prognosis in 
      patients with diabetes and non-ST segment elevation acute coronary syndromes 
      (NSTEACS) undergoing selected percutaneous coronary intervention (PCI). METHODS: 
      A total of 72 patients with diabetes and NSTEACS were randomized to either the 
      group treated with 20 mg rosuvastatin 12 hours prior to PCI with a second dose 
      administered just before PCI (n = 33), or a control group treated with standard 
      method according guideline (n = 39). Serum levels of sLox-1, hs-CRP, CK-MB, and 
      cTnI were measured prior to PCI, and at 24 hours and 30 days after PCI. The 
      30-day incidence of major adverse cardiac events (MACE) was recorded in both 
      groups. RESULTS: Compared to pre-PCI, serum levels of sLox-1 and hs-CRP of the 
      two groups were increased at 24 hours after PCI (P < 0.05); the levels of CK-MB 
      and cTnI were also improved (P < 0.01); however, the ascended values of sLox-1, 
      hs-CRP, CK-MB, and cTnI were significantly lower in the loading-dose 
      rosuvastatin-treated group than in the control-treated group. Serum levels of 
      sLox-1 and hs-CRP were higher in the loading-dose rosuvastatin-treated group than 
      in the control-treated group at 30 days after PCI (P < 0.05); compared to 
      pre-PCI, the levels of TC and LDL-C were not changed at 24 hours after PCI (P > 
      0.05) until 30 days after PCI (P < 0.05), but there were no difference between 
      the two groups. The levels of ALT and Scr had no significant difference between 
      the two groups before and after PCI; the 30-day incidence of MACE occurred in 
      6.06% of patients in the loading-dose rosuvastatin-treated group and in 23.08% of 
      patients in the control-treated group (P < 0.05). CONCLUSION: The therapy of 
      dose-loading rosuvastatin for patients with diabetes and non-ST segment elevation 
      acute coronary syndromes undergoing selected percutaneous coronary intervention 
      can attenuate the increase of serum levels of sLox-1, reduce myocardial injury 
      and inflammatory reaction caused by PCI, and also reduce the occurrence of MACE 
      30 days after PCI.
FAU - Jiao, Yungen
AU  - Jiao Y
AD  - Institute of Cardiovascular for Southeast University, Department of Cardiology, 
      Zhongda Hospital of Southeast University Medical SchoolNanjing 210000, China; 
      Department of Cardiology, First People's Hospital of Yangzhou, The Second 
      Clinical Medical School of Yangzhou UniversityYangzhou 225400, China.
FAU - Hu, Feng
AU  - Hu F
AD  - Department of Cardiology, First People's Hospital of Yangzhou, The Second 
      Clinical Medical School of Yangzhou University Yangzhou 225400, China.
FAU - Zhang, Zhengang
AU  - Zhang Z
AD  - Department of Cardiology, First People's Hospital of Yangzhou, The Second 
      Clinical Medical School of Yangzhou University Yangzhou 225400, China.
FAU - Gong, Kaizheng
AU  - Gong K
AD  - Department of Cardiology, First People's Hospital of Yangzhou, The Second 
      Clinical Medical School of Yangzhou University Yangzhou 225400, China.
FAU - Sun, Xiaoning
AU  - Sun X
AD  - Department of Cardiology, First People's Hospital of Yangzhou, The Second 
      Clinical Medical School of Yangzhou University Yangzhou 225400, China.
FAU - Li, Aihua
AU  - Li A
AD  - Department of Cardiology, First People's Hospital of Yangzhou, The Second 
      Clinical Medical School of Yangzhou University Yangzhou 225400, China.
FAU - Liu, Naifeng
AU  - Liu N
AD  - Institute of Cardiovascular for Southeast University, Department of Cardiology, 
      Zhongda Hospital of Southeast University Medical School Nanjing 210000, China.
LA  - eng
PT  - Journal Article
DEP - 20151115
PL  - United States
TA  - Int J Clin Exp Med
JT  - International journal of clinical and experimental medicine
JID - 101471010
PMC - PMC4723951
OTO - NOTNLM
OT  - Lectin-like oxidized low density lipoprotein receptor-1
OT  - acute coronary syndrome
OT  - percutaneous coronary intervention
OT  - rosuvastatin
EDAT- 2016/02/18 06:00
MHDA- 2016/02/18 06:01
PMCR- 2015/11/15
CRDT- 2016/02/18 06:00
PHST- 2015/07/17 00:00 [received]
PHST- 2015/09/02 00:00 [accepted]
PHST- 2016/02/18 06:00 [entrez]
PHST- 2016/02/18 06:00 [pubmed]
PHST- 2016/02/18 06:01 [medline]
PHST- 2015/11/15 00:00 [pmc-release]
PST - epublish
SO  - Int J Clin Exp Med. 2015 Nov 15;8(11):21565-71. eCollection 2015.